FDA Commissioner Marty Makary resigned Tuesday after 13 months leading the agency, ending a tenure marked by fierce criticism from pro-life groups, Republican lawmakers, and his own boss at the Department of Health and Human Services. A White House official told Fox News Digital that HHS Secretary Robert F. Kennedy Jr. pushed for the departure, and that Kyle Diamantis, the FDA's deputy commissioner for food, will step in as acting commissioner.
The White House official described the resignation as related to "process at the FDA" rather than any single issue, adding there was "no bad blood" between President Trump and Makary. But the facts on the ground tell a more specific story, one driven by Makary's handling of the abortion drug mifepristone, his staffing choices, and a growing revolt among social conservatives who felt sidelined by the very agency that was supposed to be on their side.
Trump, speaking to reporters as he departed the White House for a trip to China on Tuesday afternoon, called Makary a "great guy." He then offered a more telling assessment:
"He's a great doctor and he was having some difficulty, but he's going to go on and he's going to do well."
On Truth Social, the president posted a fuller farewell, thanking Makary and praising his work ethic. "So much was accomplished under his leadership. He was a hard worker, who was respected by all, and will go on to have an outstanding career in Medicine. Kyle Diamantas, a very talented person, will be put in the Acting position," Trump wrote.
But the gracious send-off came only days after the Wall Street Journal reported Friday that Trump had already signed off on a plan to fire Makary, citing three sources familiar with the matter. When asked about it Friday, Trump offered a careful non-denial: "I've been reading about it, but I know nothing about it."
That sequence, the Journal report, the presidential deflection, and then the resignation three days later, suggests the departure was less voluntary than the official framing implies. Newsmax reported that an administration official told Politico bluntly: "It was really Secretary Kennedy himself who made this decision."
The episode follows a pattern of personnel shakeups inside the Trump administration that have tested the line between resignation and removal.
At the center of the backlash was Makary's handling of mifepristone, the chemical abortion drug that has become a defining issue for the pro-life movement. Under Makary's leadership, the FDA left intact rules allowing mifepristone to be prescribed online and shipped through the mail. The agency also approved a new generic version of the pill last year.
For pro-life groups that spent years fighting to restrict the drug's distribution, those decisions amounted to a betrayal by an administration they had counted on as an ally.
Live Action president Lila Rose, speaking to Fox News Digital ahead of the resignation, had this to say:
"President Trump and Health and Human Services Secretary Kennedy must end this now, remove Commissioner Makary, stop the mail order abortion scheme, and pull these child-killing drugs from the market."
Republican Missouri Sen. Josh Hawley was even more pointed. He called the resignation "welcome news" on X Tuesday afternoon and followed up with a detailed indictment of Makary's record:
"Dr. Makary was uniquely destructive to the prolife movement. He attempted to place pro-abortion lawyers in key positions. He slow walked a vitally necessary review of the abortion drug mifepristone. He used his discretion to approve a new abortion drug when the data shows it sends 1 in 10 women to the emergency room. He froze out prolife leaders and repeatedly stonewalled Congress. His resignation is an opportunity for the FDA to reset."
Hawley's charge that Makary tried to install "pro-abortion lawyers in key positions" and froze out pro-life leaders echoes complaints that had been building for months inside the administration itself. Earlier in May, a Trump administration official told Fox News Digital that Makary's approach had made "every pro-life advocate" feel like "their concerns are an afterthought."
That same official offered a blunt summary: "What a mess Makary turned out to be." And then: "The arrogance is stunning."
Makary's departure does not resolve the larger tension within the Republican coalition over abortion policy, a tension that has been building since the Dobbs decision and has produced real electoral consequences.
Susan B. Anthony Pro-Life America President Marjorie Dannenfelser told the Wall Street Journal earlier in May that "Trump is the problem" when it comes to abortion issues falling off for the GOP in recent years. Dannenfelser said candidates who want her group's $160 million in the midterms and the 2028 presidential election must commit "to pro-life action at the national level."
That is a significant amount of money attached to a specific demand, and it signals that pro-life organizations are not content to wait quietly while the FDA and other agencies drift on the issue. The days of speculation leading up to Makary's exit only sharpened the sense that the administration was caught between its pro-life base and an FDA commissioner who was not delivering what that base expected.
The political math is not complicated. Pro-life voters are a cornerstone of the Republican coalition. When the FDA, under a Republican president, approves a generic abortion pill and preserves mail-order access, those voters notice. And they remember.
The AP reported that Makary's 13-month tenure drew complaints not only from pro-life groups but also from pharmaceutical executives and vaping lobbyists, a rare coalition of critics spanning multiple industries and interest groups. The Washington Times noted that his exit followed clashes over fruit-flavored vape policy, drug approvals, and broader internal turmoil at the agency.
Makary was set to testify before the Senate Appropriations Committee on Wednesday. That appearance will now not happen, at least not with Makary in the commissioner's chair.
Kyle Diamantis, the incoming acting commissioner, inherits an agency under political fire and a pro-life movement that has made clear it will not accept half-measures. Whether Diamantis can navigate those pressures while maintaining the FDA's regulatory functions remains an open question.
The broader pattern of internal friction within the administration, from Republican senators breaking with the White House on regulatory overreach to Trump publicly calling out his own Supreme Court appointees, suggests that managing a governing coalition is proving harder than assembling one.
And the mifepristone question is not going away. Pro-life leaders have been explicit: they want the drug pulled from the market, not merely reviewed. They want the mail-order pipeline shut down. They want an FDA that treats their concerns as central, not peripheral.
Makary, whatever his merits as a physician and administrator, failed to deliver on that front. His departure is the consequence. The question now is whether the administration treats it as a course correction, or just a personnel swap.
Trump's influence within the Republican Party remains formidable, but influence without follow-through on core promises has a shelf life. Pro-life voters did not send this administration to Washington to watch the FDA greenlight generic abortion pills and call it progress.
Personnel is policy. The pro-life movement just proved it can still enforce that rule. The next FDA chief would do well to take the lesson.
